<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="137843">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01306656</url>
  </required_header>
  <id_info>
    <org_study_id>AAAF1797</org_study_id>
    <secondary_id>R01DK084986-01A</secondary_id>
    <secondary_id>R01DK084986-01</secondary_id>
    <nct_id>NCT01306656</nct_id>
  </id_info>
  <brief_title>Vitamin D Repletion in Primary Hyperparathyroidism</brief_title>
  <official_title>Randomized Controlled Trial of Vitamin D Repletion Regimens in Primary Hyperparathyroidism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Columbia University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will look at the effect of 2 treatment regimens that contain vitamin D in a
      six-month treatment trial of patients with PHPT who are vitamin D deficient. Patients will
      be assigned randomly to one of 2 regimens, and will be followed with tests of their blood,
      urine and bones. This study should provide important information on the effect of vitamin D
      therapy in patients with PHPT. In addition, data from this study will guide physicians as to
      how best to treat their patients who have PHPT and vitamin D deficiency.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary hyperparathyroidism (PHPT) is a common disease in which the parathyroid glands
      produce excessive amounts of parathyroid hormone (PTH), which regulates calcium levels. In
      primary hyperparathyroidism, high levels of PTH remove too much calcium from bones and
      deposit the excess calcium in the blood, which is then filtered into the urine by the
      kidneys. Bone health is threatened by the excess calcium loss which weakens the structure of
      the bones.

      Many patients with primary hyperparathyroidism also have low vitamin D (25OHD) levels which
      is thought to further impair bone health. Recent medical guidelines recommend treating
      patients with primary hyperparathyroidism who have low vitamin D levels with oral vitamin D
      but the optimal vitamin D dose and rate of repletion is unclear. It is, therefore, important
      to determine if replenishing Vitamin D will improve bone health in primary
      hyperparathyroidism, and if so, to assess the impact of the rate of vitamin D is repletion.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum Parathyroid hormone level</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bone-specific alkaline phosphatase</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Areal bone mineral density of the lumbar spine</measure>
    <time_frame>6 months</time_frame>
    <description>measured by DXA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trabecular bone density at the forearm</measure>
    <time_frame>6 months</time_frame>
    <description>Measured by high resolution peripheral quantitative computed tomography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volumetric bone density of the spine</measure>
    <time_frame>6 months</time_frame>
    <description>Assessed by central quantitative computed tomography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Elastic Stiffness at the radius as assessed by finite element analysis of HRpQCT images</measure>
    <time_frame>6 months</time_frame>
    <description>Elastic stiffness will be calculated from HRpQCT images of distal radius and distal tibia and converted to a ÂµFE model.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Calcium Concentration</measure>
    <time_frame>Month 1, 3, 6</time_frame>
    <description>Participants whose serum calcium concentration rise above 12 milligrams per deciliter (mg/dL) will stop study medications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary Calcium Level</measure>
    <time_frame>Month 1, 3, 6</time_frame>
    <description>Urinary calcium &gt; 400 milligrams/day (mg/d)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants that developed nephrolithiasis</measure>
    <time_frame>1, 3, and 6 months</time_frame>
    <description>Participants who develop nephrolithiasis will stop study medications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum C-terminal telopeptide of type I collagen</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Areal bone mineral density of the hip</measure>
    <time_frame>6 months</time_frame>
    <description>Measured by DXA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trabecular bone density at the tibia</measure>
    <time_frame>6 months</time_frame>
    <description>measured by high resolution peripheral quantitative computed tomography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cortical bone density of the radius</measure>
    <time_frame>6 months</time_frame>
    <description>Measured by high resolution peripheral quantitative computed tomography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cortical bone density at the tibia</measure>
    <time_frame>6 months</time_frame>
    <description>measured by high resolution quantitative computed tomography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volumetric bone density of the hip</measure>
    <time_frame>6 months</time_frame>
    <description>measured by central quantitative computed tomography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Elastic Stiffness at the tibia as assessed by finite element analysis of HRpQCT images</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants achieving a serum vitamin D level greater than or equal to 30 nanograms per milliliter</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Primary Hyperparathyroidism</condition>
  <condition>Vitamin D Deficiency</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10,000 IU Vitamin D3 plus a multivitamin with 400 IU vitamin D</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo plus a multivitamin with 400 IU vitamin D</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>10,000 IU Vitamin D3</intervention_name>
    <description>Month 1: 20,000 IU vitamin D3 once a week, plus daily multivitamin with 400 IU vitamin D.
Months 2-6: 10,000 IU vitamin D3 once a week, plus daily multivitamin with 400 IU vitamin D.</description>
    <arm_group_label>Group 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Month 1: Placebo once a week plus daily multivitamin with 400 IU vitamin D.
Months 2-6: Placebo every week plus daily multivitamin with 400 IU vitamin D.</description>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosed PHPT, defined by an elevated serum calcium level (we will not study
             normocalcemic PHPT) with elevated or inappropriately normal PTH levels.

          -  Vitamin D3 less than 30 ng/ml

        Exclusion Criteria:

          -  Patients with familial hyperparathyroid syndromes

          -  Current or past use of the following medications: bisphosphonate within past 2 years,
             use of lithium or thiazide diuretics, current use of cinacalcet, use of aluminum
             containing medications, cimetidine, colestipol, or orlistat

          -  Malignancy, except cured basal or squamous cell skin carcinoma or other cured cancers
             that are at least five years free from recurrence

          -  History or current diagnosis of certain medical diseases (including sarcoidosis,
             active infectious granulomatous disease, HIV/AIDS, chronic kidney disease (serum
             creatinine &gt; 1.5 mg/dL), liver disease; GI diseases known to affect calcium
             metabolism; secondary hyperparathyroidism);

          -  We will also exclude patients with calcium above 11.5 mg/dL, urine calcium above 350
             mg/day, and active nephrolithiasis because vitamin D repletion could potentially
             exacerbate hypercalcemia or hypercalciuria

          -  Other exclusions include protected individuals (institutionalized), prisoners, and
             any other prospective participant who might not be able to give voluntary informed
             consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shonni J Silverberg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marcella Walker, MD</last_name>
    <phone>212-305-7225</phone>
    <email>mad2037@columbia.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mariana Bucovsky</last_name>
    <phone>212-305-7225</phone>
    <email>mb3523@columbia.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marcella Walker, MD, MS</last_name>
      <phone>212-305-7225</phone>
    </contact>
    <investigator>
      <last_name>Shonni J. Silverberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Angela Carelli, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marcella D. Walker, MD, MS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elizabeth Shane, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <lastchanged_date>December 6, 2016</lastchanged_date>
  <firstreceived_date>February 10, 2011</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Columbia University</investigator_affiliation>
    <investigator_full_name>Shonni J. Silverberg</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Endocrinology</keyword>
  <keyword>Metabolic Bone Disease</keyword>
  <keyword>Primary Hyperparathyroidism</keyword>
  <keyword>PHPT</keyword>
  <keyword>Vitamin D Deficiency</keyword>
  <keyword>Bone Mineral Density</keyword>
  <keyword>Hyper-calcemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hyperparathyroidism</mesh_term>
    <mesh_term>Vitamin D Deficiency</mesh_term>
    <mesh_term>Hyperparathyroidism, Primary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
